Aditya Birla Fashion gains on healthy Q3FY20 numbers
Aditya Birla Fashion gains on healthy Q3FY20 numbers

Aditya Birla Fashion gains on healthy Q3FY20 numbers

Nidhi Jani Article rating: 3.2

Its consolidated revenue for the quarter Q3FY20 came in at Rs 2,582.74 crore, as against Rs 2,281.55 crore in the corresponding quarter last year, registering 13.2 per cent YoY increase. EBITDA for the quarter grew by 136.1 per cent YoY to Rs 408.29 crore, as against Rs 172.93 crore in the corresponding quarter last year, with a corresponding margin expansion of 823 bps.

RBI combats inflation; hold rates steady
RBI combats inflation; hold rates steady

RBI combats inflation; hold rates steady

Rishikesh Gaikwad Article rating: 5.0

Reserve Bank of India (RBI) held rates steady on Thursday, as it sought to support faltering growth and avoid stoking already high inflation levels.

PSP Projects get LoA worth Rs 41.68 crore
PSP Projects get LoA worth Rs 41.68 crore

PSP Projects get LoA worth Rs 41.68 crore

Anthony Fernandes Article rating: 4.5

PSP Projects announced on Thursday that it was in receipt of Letter of Authorisation (LOA) for work orders worth Rs 41.68 crore, excluding GST for an institutional and government project.

NFO Analysis: IDFC Emerging Businesses Fund
NFO Analysis: IDFC Emerging Businesses Fund

NFO Analysis: IDFC Emerging Businesses Fund

Henil Shah Article rating: 3.5

It is expected that 2020 might prove to be a turnaround year for small-cap stocks. In this anticipation, IDFC Mutual Fund has launched IDFC Emerging Businesses Fund, an open-ended equity scheme. Read on to find out whether is it worth subscribing or not.

Rites report Rs 140 crore profit in Q3FY20
Rites report Rs 140 crore profit in Q3FY20

Rites report Rs 140 crore profit in Q3FY20

Amir Shaikh Article rating: 4.5

Rites reported its third quarter result of FY20 today, in which, its revenue from operations increased by nearly 16 per cent, YoY to Rs 602.6 crore in the quarter.

Granules India shines on getting USFDA nod for Colchicine tablets
Granules India shines on getting USFDA nod for Colchicine tablets

Granules India shines on getting USFDA nod for Colchicine tablets

Apurva Joshi Article rating: 5.0

Granules India’s wholly-owned foreign subsidiary-Granules Pharmaceuticals, Inc, had filed the Abbreviated New Drug Application (ANDA) for Colchicine tablets USP, 0.6 mg for which it has received US Food & Drug Administration (USFDA) approval.

Tips to invest in mutual funds
Tips to invest in mutual funds

Tips to invest in mutual funds

Henil Shah Article rating: 4.3

Many of you might already be investing and some are still giving it a thought. So, here are a few tips of investing into mutual funds that would help you in getting a better experience.

Know your behavioural biases before investing!
Know your behavioural biases before investing!

Know your behavioural biases before investing!

Rishikesh Gaikwad Article rating: 3.8

Behavioural biases can hurt your financial well-being, as they tend to result in suboptimal decisions. Being aware of your behavioural biases help an individual take better decisions and thereby, be immune from losses that are avoidable.

Dilip Buildcon bags NHAI project worth Rs 861 crore
Dilip Buildcon bags NHAI project worth Rs 861 crore

Dilip Buildcon bags NHAI project worth Rs 861 crore

Apurva Joshi Article rating: 3.0

Dilip Buildcon Limited has been declared as L-1 bidder for a new Hybrid Annuity Model (HAM) project, four-lane with paved shoulder configuration of Patrapali-Katghora (Km 53.300 to Km 92.600) Pkg-II of Bilaspur-Katghora section of NH-111, New NH-130 in the state of Chhattisgarh under Bharatmala on Hybrid Annuity Model by the National Highways Authority of lndia (NHAI).

RSS
First28992900290129022904290629072908Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR